Seres Therapeutics, Takeda & more — 3 GI company key notes

Here are three updates on GI companies from the past week:

Advertisement

The FDA granted Seres Therapeutics’ SER-287 orphan drug designation. SER-287 treats pediatric ulcerative colitis.

The FDA approved Ferring Pharmaceutical’s Clenpiq, a low-volume colonoscopy prep solution.

Takeda appointed Toshio Fujimoto, MD, to serve as the general manager of the Health Innovation Park in Shonan, Japan.

More articles on gastroenterology:
GI leader to know: Dr. Essam Quraishi of Gastrointestinal & Liver Consultants
Stock market week-in-review for 5 large GI companies — Nov. 27 to Dec. 1
How AI is improving polyp detection

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • OSF HealthCare Saint Anthony Medical Center in Rockford, Ill., has added Tarik Firozi, MD, according to an April 6 report…

  • Miami-based Gastro Health has finalized a partnership with Digestive Disease Physicians, an Alexandria, Va.-based gastroenterology practice, according to an April…

  • Birmingham (Ala.) Gastroenterology has opened a clinic in Jasper, Ala., expanding access to digestive health services in the region, the…

Advertisement

Comments are closed.